Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN PP&E (Net)

PP&E (Net) at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.94M-26.2%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$153.58M+1.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$90.9M+4.5%
Biogen logo
BiogenBIIB
$3.02B-3.7%
Globus Medical logo
Globus MedicalGMED
$557.14M+0.1%
Cytokinetics logo
CytokineticsCYTK
$82.44M+22.7%

Segments

By geography

See full
United States$755.07M—
Ireland$308.12M—

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's PP&E (net)?
BioMarin Pharmaceuticals (BMRN) reported PP&E (net) of $958.07M in Q1 2026.
How has BioMarin Pharmaceuticals's PP&E (net) changed year-over-year?
BioMarin Pharmaceuticals's PP&E (net) decreased by 7.2% year-over-year, from $1.03B to $958.07M.
What is the long-term trend for BioMarin Pharmaceuticals's PP&E (net)?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's PP&E (net) has grown at a -1.6% compound annual growth rate (CAGR), from $1.03B to $952.51M.
What does PP&E (net) mean?
The value of the company's physical assets like buildings and equipment, minus wear and tear.
How do you interpret PP&E (net)?
An increase indicates ongoing investment in manufacturing capacity or research infrastructure, while a decrease suggests depreciation is outpacing new capital expenditures.
How does PP&E (net) compare across companies?
Highly dependent on whether a company owns its manufacturing facilities or outsources production to contract manufacturers.